Abstract
During the past few months, Italy has seen the introduction of important changes to the regulatory framework applicable to clinical trials conducted in the country. On 22 December 2017, the Italian Senate adopted the long-awaited delegation law on clinical trials (‘Delegation Law’), which (among other things) mandates a reform of the Italian regulatory framework with a view to adapting it to the upcoming European Union ('EU') Clinical Trials Regulation. Earlier that month, a ministerial decree regulating the use of investigational medicinal products outside a clinical trial (‘Decree on Compassionate Use’) entered into force. Section I of this report discusses the key elements of the new Delegation Law on clinical trials. Section II briefly reviews the new Decree on Compassionate Use insofar as it concerns investigational medicinal products. Section III concludes by clarifying what are the next steps we should be watching for.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
